Year: 2024
Type: review
Abstract: Lecanemab is the second anti-amyloid monoclonal antibody that receives approval after aducanumab. The United States Food and Drug Administration granted registration to lecanemab on January 6, 2023, for the treatment of early-stage Alzheimer's disease with mild cognitive impairment or mild dementia. The mechanism of action involves the drug specifically binding to amyloid beta, leading to the inhibition of the accumulation or elimination of amyloid beta plaques, which are proteins toxic to the brain. This mechanism makes it possible to treat Alzheimer's disease. A systematic literature review has demonstrated the drug is statistically effective in reducing amyloid beta plaques in patients with Alzheimer's disease. Regarding safety information, common side effects include infusion-related reaction and abnormalities resulting from amyloid-related imaging abnormalities, such as bleeding, brain swelling, headaches, and falls.
Author: Sawekkulchol, Suwitcha
Institution: King Chulalongkorn Memorial Hospital
Language: Thai
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W7219192209